Clinical Outcomes and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A Real-World Data Analysis

A significant proportion of patients were diagnosed with mTNBC after symptom onset, limiting therapeutic intervention. Diagnosing mTNBC before symptomatic deterioration may expand treatment opportunities. Prospective evaluation of follow-up strategies and biomarkers is required, and further research should clarify treatment positioning, including paclitaxel plus bevacizumab and maintenance therapy with oral agents for biologically low-grade cases.